11 completed, 3 unknown, 1 enrolling by invitation, 1 terminated. 6 Phase 3, 4 Phase 2, 4 Phase 4, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Terminated 1 |
| Phase 2 | 4 | Completed 2, Unknown 2 |
| Phase 4 | 4 | Completed 2, Enrolling by invitation 1, Unknown 1 |
| Not applicable | 2 | Completed 2 |
| Phase 1 | 1 | Unknown 1 |
Follow Avapro: new trials by email Literature Review of Avapro trials Research Report on Avapro
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Losartan, Valsartan, Azilsartan - Covid19, SARS-CoV Infection | Phase 3 | Terminated | University of British Columbia | 341 | 2020-10-09 | 2023-02-16 |
| Multiple Treatments for Ebola Virus Disease (EVD) Azithromycin, Sunitinib and Erlotinib, Atorvastatin and Irbesartan - Ebola Virus Disease | Phase 1 / Phase 2 | Unknown | Clinical Research Management, Inc. | 150 | 2015-04-01 | 2015-03-05 |
| Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans Irbesartan, Placebo - Hypertension, Obesity | Phase 2 | Unknown | Augusta University | 30 | 2014-04-01 | 2019-06-21 |
| Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis RE-021 (Sparsentan), Irbesartan - Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Travere Therapeutics, Inc. | 109 | 2014-03-01 | 2025-05-15 |
| Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts tacrolimus, Simulect, Cellcept - Kidney Transplantation | Phase 3 | Completed | Astellas Pharma Inc | 281 | 2009-08-17 | 2024-11-01 |
| Irbesartan and Adhesion Molecules in AF irbesartan, placebo - Persistent Atrial Fibrillation | Phase 4 | Unknown | University of Magdeburg | 60 | 2009-05-01 | 2009-05-29 |
| Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan Irbesartan, Placebo matching irbesartan 150 mg - Kidney Failure, Chronic | Phase 3 | Completed | University of Aarhus | 82 | 2009-04-01 | 2013-01-08 |
| A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension irbesartan, placebo, PS433540 - Hypertension | Phase 2 | Completed | Ligand Pharmaceuticals | 261 | 2008-03-01 | 2011-09-16 |
| Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions Irbesartan, Avapro - Hypertension | Not applicable | Completed | Roxane Laboratories | 33 | 2007-08-01 | 2018-01-23 |
| Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions Irbesartan, Avapro - Hypertension | Not applicable | Completed | Roxane Laboratories | 34 | 2007-08-01 | 2018-01-23 |
| Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF) Irbesartan, Placebo - Atrial Fibrillation | Phase 3 | Completed | Bristol-Myers Squibb | 44 | 2006-07-01 | 2010-02-17 |
| Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome Irbesartan, Hydrochlorothiazide - Metabolic Syndrome, Hypertension | Phase 4 | Completed | Bristol-Myers Squibb | 400 | 2005-11-01 | 2011-04-15 |
| Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension Irbesartan/HCTZ, Irbesartan monotherapy, HCTZ monotherapy - Hypertension | Phase 3 | Completed | Bristol-Myers Squibb | 496 | 2004-10-01 | 2011-04-15 |
| Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria Ramipril + Irbesartan, Ramipril + Placebo - Albuminuria | Phase 4 | Completed | Bristol-Myers Squibb | 400 | 2004-09-01 | 2011-04-15 |
| Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension Irbesartan/HCTZ, Irbesartan monotherapy - Hypertension | Phase 3 | Completed | Bristol-Myers Squibb | 645 | 2004-09-01 | 2011-04-15 |
Hypertension (8) · Albuminuria (2) · Atrial Fibrillation (2) · Acute Kidney Injury (1) · COVID-19 (1) · Coronavirus Infections (1) · Diabetes Mellitus, Type 2 (1) · Glomerulosclerosis, Focal Segmental (1) · Hemorrhagic Fever, Ebola (1) · Hyperkalemia (1) · Kidney Failure, Chronic (1) · Metabolic Syndrome (1) · Nephrotic Syndrome (1) · Obesity (1) · Renal Insufficiency, Chronic (1)
Bristol-Myers Squibb (5) · Roxane Laboratories (2) · Astellas Pharma Inc (1) · Augusta University (1) · Baylor Research Institute (1) · Clinical Research Management, Inc. (1) · Ligand Pharmaceuticals (1) · Travere Therapeutics, Inc. (1) · University of Aarhus (1) · University of British Columbia (1) · University of Magdeburg (1)
United States (9) · Canada (5) · France (5) · Germany (5) · Russia (4) · Italy (3) · Spain (3) · Israel (2) · Netherlands (2) · Australia (1) · Belgium (1) · Czechia (1) · Denmark (1) · Latvia (1) · Lithuania (1)
Jolene K Berg, MD (2) · Andreas Goette, MD (1) · Bente Jespersen, MD, DrMedSc (1) · Charlotte Strandhave, MD (1) · Christian D Peters, MD (1) · Christopher Woods, MD, MPH (1) · David L Hoover, MD (1) · Erik Sloth, MD, DrMedSc (1) · Gregory A Harshfield, PhD (1) · Howard Trachtman, M.D. (1) · Ida N Tietze, MD, PhD (1) · James A Russell, MD (1) · Jens Kristian D Jensen, MD, PhD (1) · Joel Neutel, MD (1)
PMID 17667984, PMID 23651713, PMID 26030651, PMID 26768569, PMID 30361325, PMID 30582281, PMID 33115436, PMID 35224732, PMID 36657027, PMID 38831932, PMID 39082471, PMID 39325643, PMID 39739990, PMID 40337980